Anti-ERBB2 antibody adjuvant therapy

  • US 8,591,897 B2
  • Filed: 04/06/2006
  • Issued: 11/26/2013
  • Est. Priority Date: 05/13/2005
  • Status: Active Grant
First Claim
Patent Images

1. A method of adjuvant therapy comprising administering to a human subject with nonmetastatic HER2 positive breast cancer, following definitive surgery, anthracycline/cyclophosphamide (AC) based chemotherapy, followed by sequential administration of a taxoid and trastuzumab or an antibody that blocks binding of trastuzumab to HER2.

View all claims

    Thank you for your feedback